HSV Flashcards
(18 cards)
Herpesviridae is the
- 2nd most common cause of viral disease in humans (after?
Herpesviridae is the
- 2nd most common cause of viral disease in humans (after flu & cold viruses)
- Name origin: Greek – herpein (“to creep”)
- Key feature: Latency with periodic reactivation
What are the Genome & Structure of HSV?
Genome & Structure
- dsDNA virus (125–229 kb)
- Icosahedral nucleocapsid
- Tegument layer surrounds the nucleocapsid
- Envelope derived from host cell membrane
- Large virion: 120–260 nm
- Encodes multiple genes for replication, immune evasion, latency
What are the Classification (by behavior, tropism, replication speed)
Subfamily | Features Latency Site Examples
Classification (by behavior, tropism, replication speed)
Subfamily | Features Latency Site Examples
| Beta | Slow replication, cytomegalic effect, restricted host range | Glands, monocytes/macrophages | CMV, HHV-6, HHV-7
Gamma | Poor replication, oncogenic potential, narrow host range | B lymphocytes | EBV, HHV-8 (KSHV) |
Alpha | Fast replication, lytic, broad host range | Sensory & cranial ganglia | HSV-1, HSV-2, VZV, Herpes B |
Human Herpesviruses (HHVs)
** Virus** Common Name Subfamily Key Diseases they cause?
Human Herpesviruses (HHVs)
** Virus** Common Name Subfamily Key Diseases
HSV-1 | Herpes Simplex Virus 1 Alpha | Oral herpes, encephalitis
HSV-2 | Herpes Simplex Virus 2 | Alpha | Genital herpes
VZV | Varicella-Zoster Virus Alpha | Chickenpox, shingles
CMV | Cytomegalovirus Beta | Congenital CMV, retinitis
HHV-6/7 | Human Herpesvirus 6 & 7
Beta | Roseola infantum (exanthem subitum)
EBV | Epstein-Barr Virus
Gamma | Infectious mononucleosis, Burkitt lymphoma, NPC |
HHV-8 | Kaposi Sarcoma–associated HV |
Gamma | Kaposi sarcoma, Castleman disease
⏩ Note: Herpes B virus infects macaques but causes fatal encephalitis in humans
Epidemiology
- Universal infections: HSV-1, VZV, EBV, HHV-6/7
- HSV-2: 15–50% in adults (↑ in developing countries)
- CMV: 40–70%
- HHV-8: <5% (↑ in immunocompromised)
- No sex predilection
Epidemiology
- Universal infections: HSV-1, VZV, EBV, HHV-6/7
- HSV-2: 15–50% in adults (↑ in developing countries)
- CMV: 40–70%
- HHV-8: <5% (↑ in immunocompromised)
- No sex predilection
Mode | Viruses Involved |
| ——————— | ——————————– |
| Saliva | HSV, CMV, EBV, HHV-6 |
| Sexual contact | HSV, CMV, HHV-8 |
| Intrauterine | HSV, CMV, VZV |
| Transplant | CMV, EBV, HHV-8 |
| Blood transfusion | CMV, EBV |
| Airborne | EBV (unique among herpesviruses) |
- Entry via:
- Endocytosis + fusion with endocytic vesicle
- Direct membrane fusion
- Receptors involved: Nectin 1/2, PDGFR, EGFR, CD21, CD46, CD134, Integrins, MHC II
- Replication site: Nucleus
- Shedding without symptoms: HSV, EBV, CMV, HHV-6/7 (esp. oral mucosa)
- Symptomatic disease: From lytic replication → skin/visceral lesions
What are the Transmission Routes of HSV?
Mode & Viruses Involved
Transmission Routes
Mode & Viruses Involved
Saliva | HSV, CMV, EBV, HHV-6
Sexual contact | HSV, CMV, HHV-8
Intrauterine | HSV, CMV, VZV
Transplant | CMV, EBV, HHV-8
Blood transfusion | CMV, EBV
Airborne | EBV (unique among herpesviruses)
Replication & Pathogenesis
Replication & Pathogenesis
- Entry via:
- Endocytosis + fusion with endocytic vesicle
- Direct membrane fusion
- Receptors involved: Nectin 1/2, PDGFR, EGFR, CD21, CD46, CD134, Integrins, MHC II
- Replication site: Nucleus
- Shedding without symptoms: HSV, EBV, CMV, HHV-6/7 (esp. oral mucosa)
- Symptomatic disease: From lytic replication ➡️ skin/visceral lesions
Latency and Reactivation (Detailed Explanation)
Latency:
- Herpesviruses establish life-long latency after primary infection.
-
Latency sites vary by virus:
HSV-1&2
VZV
ENV
CMV
HHV-6&7
HHV-8
- HSV-1/2: sensory and cranial ganglia
- VZV: dorsal root ganglia
- EBV: B lymphocytes
- CMV: monocytes/macrophages
- HHV-6/7: CD4+ T cells
- HHV-8: B cells and endothelial cells
What’s the Mechanisms of latency:
Mechanisms of latency:
- Viral genome remains episomal (non-integrated circular DNA) inside host cell nucleus.
- Limited gene expression: avoids immune detection.
- LAT (Latency-associated transcripts) in HSV suppress apoptosis and regulate reactivation.
- EBV expresses EBNA-1 for genome maintenance and LMPs for B-cell transformation.
- Viral microRNAs suppress immediate-early (IE) gene expression ➡️ prevents reactivation signals.
- Some viral proteins are sequestered in the cytoplasm during latency.
What are the Triggers for Reactivation:
What are the clinical relevance of this latency and reactivation?
Triggers for Reactivation:
- Stress
- Fever (e.g., other infections)
- UV light/radiation
- Immunosuppression (HIV, chemotherapy)
- Nerve trauma (e.g., dental work)
- Hormonal changes (e.g., menstruation)
Clinical relevance: Latency explains:
- Recurrent cold sores (HSV-1)
- Genital herpes recurrences (HSV-2)
- Shingles in the elderly or immunosuppressed (VZV)
What are the Clinical Features of these Viruses? (with relevant mechanisms)
Clinical Features by Virus (with relevant mechanisms)
HSV-1
- Acute Gingivostomatitis: Primary infection in children.
- Herpetic Whitlow: Painful lesion on fingers from inoculation.
- Keratoconjunctivitis: Involves cornea → risk of blindness.
- Eczema herpeticum: Generalized HSV infection in eczematous skin.
- Encephalitis: HSV-1 is the most common cause of sporadic viral encephalitis (temporal lobe involvement).
HSV-2
- Genital herpes: Painful vesicles, high recurrence.
- Aseptic meningitis: More common in women.
- Neonatal herpes: Acquired during delivery.
- Cutaneous herpes: Vesicles in immunocompromised.
- Gingivostomatitis: Less common than HSV-1.
VZV
- Varicella (chickenpox): Primary infection, vesicular rash.
- Zoster (shingles): Reactivation → dermatomal vesicular rash.
EBV
- Infectious mononucleosis: Fever, sore throat, lymphadenopathy.
- Oral hairy leukoplakia: White patches on tongue (seen in AIDS).
- Hepatitis, pneumonia, encephalitis: Less common.
-
EBV-associated malignancies:
- Burkitt lymphoma (c-MYC translocation)
- Nasopharyngeal carcinoma (epithelial cells)
- Hodgkin lymphoma (Reed-Sternberg cells)
CMV
- Congenital CMV: Sensorineural hearing loss, intracranial calcifications.
- Mononucleosis: Heterophile-negative (unlike EBV).
- Retinitis: Common in AIDS (CD4 <50).
- Pneumonia: Especially in transplant recipients.
HHV-6 & HHV-7
- Exanthem subitum (Roseola infantum): High fever → resolves → then rash.
- Encephalitis: Rare.
HHV-8
- Kaposi sarcoma: Vascular tumor in AIDS.
- Castleman disease: Lymphoproliferative.
- Febrile exanthem: Non-specific.
Herpes B Virus
- Rare but dangerous zoonosis (monkey bites).
- Mucocutaneous lesions, encephalitis: Fatal without rapid treatment.
What are the Oncogenes of (EBV & HHV-8)
Oncogenesis (EBV & HHV-8)
Only two oncogenic herpesviruses:
-
EBV:
- LMP-1: Mimics CD40 ⏩ B cell proliferation
- EBNA-1: Maintains viral genome during latency
-
HHV-8:
- K1, K12, ORF74: Promote angiogenesis and immune evasion
Key insight: These viruses establish latency in immune cells, manipulate signaling pathways, and evade immune detection to promote transformation.
What are the clinical symptoms of HSV?
Samples : for which HSV specie?
What are the ** Laboratory Diagnosis of Herpesvirus Infections**? Which is the Gold Standard & what will you see?
Clinical Clue First
- Many primary infections are diagnosed clinically due to their classic signs:
- HSV: grouped vesicles, gingivostomatitis, genital ulcers.
- VZV: dermatomal rash (shingles), chickenpox in children.
- EBV: sore throat, lymphadenopathy, splenomegaly.
Sample Types (Specimens)
Useful based on clinical context:
- Vesicular fluid, skin swab ⏩ HSV, VZV
- Saliva ⏩ EBV, CMV, HHV-6
- Urine, stool, semen ⏩ CMV
- CSF ⏩ HSV/CMV encephalitis
- Brain biopsy → Severe CMV or HSV CNS disease
- Conjunctival swab → HSV keratitis
- Blood ⏩ CMV viremia (transplant patients)
Direct Examination Techniques
-
Light Microscopy (LM):
- Look for cytopathic effects (CPEs):
- Multinucleation
- Margination of chromatin
- Cowdry A intranuclear inclusion bodies
- Look for cytopathic effects (CPEs):
-
Electron Microscopy (EM):
- Visualizes virions directly (used mainly in research).
-
Fluorescent Microscopy (FM):
- Immunofluorescent staining detects viral antigens in tissue or cells.
Viral Culture (Gold Standard but Slow)
- Cell lines: Human fibroblasts, Vero cells, umbilical cord lymphocytes.
- HSV/VZV: Ballooning of cells, syncytia.
- CMV: “Owl’s eye” inclusion bodies in fibroblasts.
Serology
- Detect virus-specific antibodies (IgM, rising IgG):
- Complement fixation, neutralization, ELISA.
- Useful in primary infection or congenital CMV.
- Less helpful in reactivation (antibodies already present).
PCR – Gold Standard for CNS Herpesvirus Infections
- High sensitivity and specificity.
-
Uses:
- HSV/CMV/EBV DNA in CSF (encephalitis, meningitis).
- CMV/EBV viral load in transplant patients.
- HHV-6/7 in febrile seizures or encephalitis.
What are the Treatment of Herpesvirus Infections?
2. Treatment of Herpesvirus Infections
Key Principles
- Most drugs inhibit viral DNA polymerase.
- All act only on replicating virus, not latent forms.
- Most require activation by viral kinases (except a few).
Drugs That Require Viral Enzyme Phosphorylation
-
Acyclovir, Valacyclovir, Famciclovir, Penciclovir:
- First phosphorylated by HSV/VZV thymidine kinase.
- Then activated by host kinases.
- Use: HSV-1/2, VZV.
-
Ganciclovir:
- Activated by CMV protein kinase UL97.
- Use: CMV infections.
Drugs That Do NOT Require Phosphorylation
- Foscarnet: Directly inhibits DNA polymerase. Use when resistance develops (e.g., thymidine kinase-deficient HSV).
- Cidofovir: Already monophosphorylated → active against CMV, adenovirus, etc.
Special Cases
- Alpha Interferon: Used in Kaposi’s sarcoma (HHV-8).
- Vinblastine: Used for severe or disseminated Kaposi’s sarcoma.
- Steroids: For severe EBV-related complications (e.g., airway obstruction in mononucleosis).
What are the Clinical Limitation?
Clinical Limitation
-
No proven clinical benefit of antivirals for:
- HHV-6, HHV-7
- HHV-8 (except in Kaposi’s)
- EBV (except oral hairy leukoplakia)
3. Latency & Future Therapeutic Strategies
Current Antivirals = No Effect on Latency
What are the Emerging Approaches?
3. Latency & Future Therapeutic Strategies
Current Antivirals = No Effect on Latency
Emerging Approaches
-
Histone Deacetylase (HDAC) Inhibitors
- Drugs: Trichostatin A, Trapoxin B, Vorinostat, Belinostat.
- Mechanism: Reactivate latent virus so it becomes susceptible to antivirals.
- Concept: “Shock and kill” (used in HIV research too).
- Research stage, not routine clinical use yet.
-
HLA-Matched Cytotoxic T Cell Infusion
- Adoptive immunotherapy.
- Especially for EBV- or CMV-related disease in immunocompromised patients (e.g., post-transplant).
- Provides specific immunity.
Clinical Integration Tips
- Recurrent genital ulcers ⏩ Start acyclovir empirically.
- Temporal lobe encephalitis in adult ⏩ Send CSF PCR for HSV-1 and start acyclovir immediately.
- Congenital CMV suspicion ⏩ PCR from urine, consider ganciclovir.
- HIV patient with vision loss ⏩ Think CMV retinitis, treat with ganciclovir or foscarnet.